These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Hess E; Sperschneider H; Stein G Nephrol Dial Transplant; 1996 Apr; 11(4):749-751. PubMed ID: 8671881 [No Abstract] [Full Text] [Related]
7. ACE inhibitors do not decrease rHuEpo response in patients with end-stage renal failure. Sánchez JA Nephrol Dial Transplant; 1995; 10(8):1476-7. PubMed ID: 8538957 [No Abstract] [Full Text] [Related]
8. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY; J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432 [TBL] [Abstract][Full Text] [Related]
9. Anaemia due to ACE inhibitors and losartan in patients with renal failure. Prescrire Int; 1999 Dec; 8(44):179-80. PubMed ID: 11503817 [TBL] [Abstract][Full Text] [Related]
10. Intensity of hemodialysis and response to erythropoietin. Kotanko P N Engl J Med; 1996 Jun; 334(25):1670; author reply 1670-1. PubMed ID: 8628371 [No Abstract] [Full Text] [Related]
11. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?]. Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433 [No Abstract] [Full Text] [Related]
12. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan. Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890 [TBL] [Abstract][Full Text] [Related]
13. Lymphocyte subset counts in CAPD patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors. Grzegorzewska AE; Leander M Perit Dial Int; 2002; 22(5):625-8. PubMed ID: 12455577 [No Abstract] [Full Text] [Related]
14. Long-term renoprotective effect of combination therapy with prostaglandin E1 and angiotensin-converting enzyme inhibitor in patients with chronic renal failure. Nakayama Y; Nonoguchi H; Kiyama S; Kohda Y; Inoue T; Tomita K Hypertens Res; 2005 Sep; 28(9):733-9. PubMed ID: 16419646 [TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance. DeLong M; Logan JL; Yong KC; Lien YH Nephrol Dial Transplant; 2005 Mar; 20(3):585-90. PubMed ID: 15735242 [TBL] [Abstract][Full Text] [Related]
16. Loss of captopril-bound Fe by end-stage renal failure patients during hemodialysis. Averbukh Z; Berman S; Kishinevsky E; Feldman L; Cohn M; Rapoport M; Galperin E; Dishi V; Weissgarten J J Nephrol; 2004; 17(1):101-6. PubMed ID: 15151265 [TBL] [Abstract][Full Text] [Related]
17. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin. Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211 [TBL] [Abstract][Full Text] [Related]
19. [Physiopathology and therapy of chronic kidney failure]. Sakai O Nihon Naika Gakkai Zasshi; 1995 Mar; 84(3):480-4. PubMed ID: 7751793 [No Abstract] [Full Text] [Related]
20. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H Panminerva Med; 2003 Mar; 45(1):59-62. PubMed ID: 12682621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]